MicroRNAs: Allies or Foes in erythropoiesis?

Byon, John; Papayannopoulou, Thalia

doi:10.1002/jcp.22729

Cited by 34 publications

(39 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There is growing evidence that miRNAs regulate hematopoiesis in both hematopoietic stem cells and committed progenitor cells [17][18][19][20][21][22][23][24][25]. Deregulated miRNA profiles have been reported in MPN patients during in vitro erythroid differentiation as well as in peripheral blood granulocytes, platelets, and reticulocytes [26,27].…”

Section: Introductionmentioning

confidence: 99%

MicroRNA deregulation in polycythemia vera and essential thrombocythemia patients

Zhan

Cardozo

et al. 2013

Blood Cells, Molecules, and Diseases

View full text Add to dashboard Cite

Polycythemia vera (PV) and essential thrombocythemia (ET) are the two most common myeloproliferative neoplasms. The same JAK2 V617F mutation can be found in both disorders and is able to recapitulate many of the phenotypic abnormalities of these diseases in the murine models. The disease phenotype is also influenced by other unknown genetic or epigenetic factors. MicroRNAs (miRNA) are 18-24 nucleotides single-stranded non-protein-coding RNAs that function primarily as gene repressors by binding to their target messenger RNAs. We performed miRNA expression profiling by oligonucleotide microarray analysis in purified peripheral blood CD34+ cells from eight JAK2 V617F -positive PV patients and six healthy donors. A quantitative reverse-transcription polymerase chain reaction assay was used to verify differential miRNA expression. Since erythrocytosis is the only feature that distinguishes PV from ET, we also compared specific miRNA expression in the nucleated erythroid cells directly descended from the early erythroid progenitor cells of PV and ET patients. Our data indicate that significant miRNA deregulation occurs in PV CD34+ cells and confirm a genetic basis for the gender-specific differences that characterize PV with respect to miRNA. The results of our study also suggest that deregulated miRNAs may represent an important mechanism by which the PV erythrocytosis and ET thrombocytosis phenotypes are determined.

show abstract

Section: Introductionmentioning

confidence: 99%

MicroRNA deregulation in polycythemia vera and essential thrombocythemia patients

Zhan

Cardozo

et al. 2013

Blood Cells, Molecules, and Diseases

View full text Add to dashboard Cite

show abstract

“…In mice lacking Ago2 Gene, defective B cells and erythroid maturation as well as increased basophilic erythroblasts together with significant reduction in mature orthochromatic erythroblasts is observed (Cheloufi et al, 2010). It is not clear how the reduction or absence of Ago2 impairs erythropoiesis, and its impact on expression of miRNAs is a suggested mechanism because the lack of Ago2 protein reduces the expression level of miRNAs, including miR-451 (O'Carroll et al, 2007;Byon and Papayannopoulou, 2012). It has also been shown that the expression level of miRNA-376a is high in early precursor cells and is reduced during cell differentiation.…”

Section: Role Of Mirnas In Erythropoiesismentioning

confidence: 96%

“…There is a high expression of miR-126 in hematopoietic precursors, while the expression of it is reduced in the process of differentiation into erythroid cells in vivo (Byon and Papayannopoulou, 2012). In addition to PTPN9, expression suppression of other downstream target (s) by miR-126 may be involved in erythropoiesis inhibition, and further studies are needed to identify them (Huang et al, 2011;Byon and Papayannopoulou, 2012). miR-191: During the development of RBCs, nuclear chromatin is fully compressed until the reticulocytes lose their nucleus.…”

Section: Role Of Mirnas In Erythropoiesismentioning

confidence: 99%

“…Thus, miR-144 and EKLF constitute a negative feedback loop that results in reduced level of EKLF (Fig. 2) (Byon and Papayannopoulou, 2012).…”

Section: Mirna Expression/function In Rbc Disordersmentioning

confidence: 99%

“…Impaired expression of miRNAs may be important in development or aggravation of a number of erythroid disorders, including impaired hemoglobin synthesis that causes genetic diseases like thalassemia in humans (Byon and Papayannopoulou, 2012). The human α-globin cluster has three functional α-globin genes including αI, α II and z, which are differently expressed during embryonic and adult erythropoiesis, respectively (Fig.…”

Section: Mirna Expression/function In Rbc Disordersmentioning

confidence: 99%

See 2 more Smart Citations

MicroRNAs in erythropoiesis and red blood cell disorders

et al. 2015

View full text Add to dashboard Cite

MicroRNAs (miRNAs) are 19-24 nucleotide non-coding ribonucleic acids binding DNA or RNA and controlling gene expression via mRNA degradation or its transcription inhibition. Erythropoies is a multi step differentiation process of erythroid progenitors to nucleate red blood cells. Maturation, proliferation and differentiation of red blood cells is affected by erythroid factors, signaling pathways in niche of hematopoietic cells, transcription factors as well as miRNAs. Expression of different types of miRNAs during erythroid development provides a background for the study of these molecules to control erythroid differentiation and maturation as well as their use as diagnostic and prognostic markers to treat erythroid disorders like thalassemia, sickle cell disease and erythrocyte enzyme deficiencies. In this paper, with reference to biosynthesis of miRNAs, their function in normal and anemic erythropoiesis has been investigated. The target molecule of each of these miRNAs has been cited in an attempt to elucidate their role in erythropoiesis.

show abstract

On the trail of blood doping—microRNA fingerprints to monitor autologous blood transfusions in vivo

Mussack

Wittmann²,

Pfaffl

2021

American J Hematol

View full text Add to dashboard Cite

Autologous blood doping refers to the illegal re‐transfusion of any quantities of blood or blood components with blood donor and recipient being the same person. The re‐transfusion of stored erythrocyte concentrates is particularly attractive to high‐performance athletes as this practice improves their oxygen capacity excessively. However, there is still no reliable detection method available. Analyzing circulating microRNA profiles of human subjects that underwent monitored autologous blood transfusions seems to be a highly promising approach to develop novel biomarkers for autologous blood doping. In this exploratory study, we randomly divided 30 healthy males into two different treatment groups and one control group and sampled whole blood at several time points at baseline, after whole blood donation and after transfusion of erythrocyte concentrates. Hematological variables were recorded and analyzed following the adaptive model of the Athlete Biological Passport. microRNA profiles were examined by small RNA sequencing and comprehensive multivariate data analyses, revealing microRNA fingerprints that reflect the sampling time point and transfusion volume. Neither individual microRNAs nor a signature of transfusion‐dependent microRNAs reached superior sensitivity at 100% specificity compared to the Athlete Biological Passport (≤11% 6 h after transfusion versus ≤44% 2 days after transfusion). However, the window of autologous blood doping detection was different. Due to the heterogenous nature of doping, with athletes frequently combining multiple medications in order to both gain a competitive advantage and interfere with known testing methods, the true applicability of the molecular signature remains to be validated in real anti‐doping testings.

show abstract

MicroRNAs: Allies or Foes in erythropoiesis?

Cited by 34 publications

References 67 publications

MicroRNA deregulation in polycythemia vera and essential thrombocythemia patients

MicroRNA deregulation in polycythemia vera and essential thrombocythemia patients

MicroRNAs in erythropoiesis and red blood cell disorders

On the trail of blood doping—microRNA fingerprints to monitor autologous blood transfusions in vivo

Contact Info

Product

Resources

About